Page last updated: 2024-08-22

platinum and veliparib

platinum has been researched along with veliparib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Curigliano, G	1
Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD	1
Appleman, L; Belani, CP; Beumer, JH; Chen, A; Chew, H; Chu, E; Diergaarde, B; Ding, F; Duan, W; Garcia, AA; Giranda, V; Hurley, RM; Ivy, SP; Ji, J; Katz, T; Kaufmann, SH; Kiesel, BF; Lee, JJ; Lin, Y; Manzo, J; Morgan, RJ; Oesterreich, S; Pahuja, S; Parchment, RE; Puhalla, S; Shepherd, SP; Stoller, R; Swisher, EM; Tan, AR; Tawbi, H; Visscher, DW; Wahner Hendrickson, AE; Yu, J; Zhang, Y	1

Trials

2 trial(s) available for platinum and veliparib

Article	Year
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer treatment and research communications, 2018, Volume: 14 Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan	2018
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms	2022

Article

Year

Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.

Cancer treatment and research communications, 2018, Volume: 14

Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan

2018

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.

Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5

Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms

2022

Other Studies

1 other study(ies) available for platinum and veliparib

Article	Year
Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care? The Lancet. Oncology, 2018, Volume: 19, Issue:4 Topics: Benzimidazoles; Carboplatin; Humans; Neoadjuvant Therapy; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Salts; Standard of Care; Triple Negative Breast Neoplasms	2018